Pacira BioSciences Participation at Healthcare Conferences
Pacira BioSciences, Inc. (NASDAQ: PCRX), renowned for its transformative approach to non-opioid pain management, is set to engage in two notable healthcare conferences. These events reflect Pacira's dedication to advancing patient care and fostering professional dialogue within the healthcare community.
Upcoming Conferences
Firstly, Pacira will partake in the Jefferies London Healthcare Conference, scheduled for Tuesday, November 18, at 1:30 PM GMT. This event provides an excellent opportunity for investors and healthcare professionals to gain insights into the company's innovative strategies and product developments.
Details of Participation
Following this, the company will also be present at the 37th Annual Piper Sandler Healthcare Conference on Tuesday, December 2, at 1:30 PM ET. Both conferences will feature an analyst-led fireside chat, which promises an engaging discussion about the future of non-opioid therapies in pain management.
Accessing Live Events
For those interested, live audio of the sessions can be accessed through the company’s 'Events' page on its website. This accessibility allows wider engagement among shareholders and the general public, fostering greater transparency.
Event Replays
A replay of the presentations will also be available for two weeks post-event, ensuring that all interested parties have the opportunity to catch up on critical discussions and insights shared during these sessions.
About Pacira BioSciences
Pacira BioSciences is at the forefront of developing innovative, non-opioid therapies designed to improve pain management outcomes. Their flagship product, EXPAREL, is a long-acting local analgesic approved for a variety of uses, including infiltration and nerve block procedures. Additionally, the company offers ZILRETTA, aimed at easing osteoarthritis knee pain, and ioveraº, a groundbreaking device that utilizes cold therapy to provide long-lasting pain relief without medication.
Advancements in Treatment
Continuing its commitment to pioneering therapies, Pacira is advancing the development of PCRX-201, a novel gene therapy designed for treating prevalent conditions like osteoarthritis. This represents a robust step forward in the landscape of pain management, aiming for better outcomes without the drawbacks associated with traditional opioid therapies.
Contact Information
If you need more information, you can reach out to Christian Pedetti at Pacira BioSciences via phone at (973) 254-4387 or email at Christian.pedetti@pacira.com. The company is always keen to engage with stakeholders and address queries regarding its operations and developments.
Frequently Asked Questions
What conferences will Pacira BioSciences participate in?
Pacira BioSciences will join the Jefferies London Healthcare Conference and the 37th Annual Piper Sandler Healthcare Conference.
How can I access the live audio of the events?
Live audio can be accessed on Pacira's 'Events' page, available on their official website.
What are some of the key products of Pacira BioSciences?
Pacira's primary products include EXPAREL, ZILRETTA, and ioveraº, focusing on non-opioid pain management solutions.
What is PCRX-201?
PCRX-201 is a novel gene therapy currently being developed by Pacira to treat large prevalent diseases like osteoarthritis.
Who can I contact for more information about Pacira BioSciences?
For inquiries, you can contact Christian Pedetti at (973) 254-4387 or via email at Christian.pedetti@pacira.com.